ESPR Stock Analysis: Buy, Sell, or Hold?
ESPR - Esperion Therapeutics, Inc.
$3.18
-0.01 (-0.31%)
▼
5d:
+0.63%
30d:
+1.27%
90d:
+45.87%
HOLD
MODERATE Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: Aug 04, 2026
TODAY
Get Alerted When ESPR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ESPR shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ESPR shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.23
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$6.35
49.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ESPR is currently trading at $3.18, which is considered extended relative to its 30-day fair value range of $3.15 to $3.18. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.9) compared to its historical average (38.6). Remarkably, the market is currently pricing in an annual earnings decline of 34.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ESPR is in a strong uptrend. The price is currently testing key support at $3.15. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (22th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ESPR is in a strong uptrend. The price is currently testing key support at $3.15. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (22th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.15 -
$3.18
Company Quality Score
55/100
(HOLD)
Options IV Signal
22th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
56.5%
Protect Your Profits
Holding ESPR? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 22th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($3.19)
Trading Range Analysis
30-Day Trading Range
$3.15 -
$3.18
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.35
(11.1%)
Support & Resistance Levels
Support Level
$3.15
Resistance Level
$3.19
Current Trend
Strong Uptrend
Technical data as of
Jul 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.89
Wall Street Target
$3.19
(+0.3%)
Revenue Growth (YoY)
23.2%
Profit Margin
-1.8%
Valuation Discount vs History
-34.4% cheaper
PE vs Historical
10.9 vs 38.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-34.4%
(market-implied from PE analysis)
1-Year Target
$2.86
(-10%)
2-Year Target
$2.58
(-19%)
3-Year Target
$2.32
(-27%)
3-Yr Target (if PE normalizes)
(PE: 11→39)
$8.22
(+158%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.9 to 38.6
Stabilization Target:
$11.27
(+254.4%)
PE Expansion Potential:
+254.4%
Share & Embed Analysis
Last updated: August 02, 2026 10:30 PM ET
Data refreshes hourly during market hours. Next update: 11:30 PM
Data refreshes hourly during market hours. Next update: 11:30 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ESPR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Benjamin Halladay
SELL
6424 shares
2026-03-17
Benjamin Looker
SELL
5708 shares
2026-03-17
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$112 | 52 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$663 | 48 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$113 | 45 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
Advanced ESPR Option Strategies
Professional options setups generated by AI based on today's ESPR price and gamma walls.
